After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Halozyme Therapeutics Inc. (HALO) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $51.02. The Halozyme Therapeutics Inc. has recorded 149,336 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024.
HALO belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $51.02 and fluctuated between $51.48 as its day high and $49.89 as its day low. The current market capitalization of Halozyme Therapeutics Inc. is $6.95B. A total of 1.5 million shares were traded on the day, compared to an average of 1.25M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, HALO has seen 6 BUY and 21 SELL insider trades, representing the acquisition of 60,000 and the disposition of 130,248 shares. Over the last 12 months, there were 25 BUYs and 33 SELLs from insiders. Insiders purchased 240,916 shares during that period but sold 197,402.
In the most recent transaction, Torley Helen sold 10,000 shares of HALO for 57.37 per share on Dec 15. After the transaction, the PRESIDENT AND CEO now owns 587,177 company shares. In a previous transaction on Dec 14, Torley Helen sold 10,000 shares at 58.30 per share. HALO shares that PRESIDENT AND CEO owns now total 587,177.
Among the insiders who sold shares, Torley Helen disposed of 10,000 shares on Dec 13 at a per-share price of $58.66. This resulted in the PRESIDENT AND CEO holding 587,177 shares of HALO after the transaction. In another insider transaction, LaBarre Michael J. sold 10,000 shares at $58.67 per share on Dec 13. Company shares held by the SVP, CHIEF TECHNICAL OFFICER now total 153,137.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for HALO in the last 3 months, the mean price target is $56.22 with high estimates of $68.00 and low estimates of $26.00. In terms of 52-week highs and lows, HALO has a high of $59.46 and a low of $31.36.
As of this writing, HALO has an earnings estimate of $0.51 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of $0.58 per share and a lower estimate of $0.42. The company reported an EPS of $0.47 in the last quarter, which was -4.10% lower than expectations of $0.49.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 9 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for HALO is Overweight with a score of 4.44. A total of 7 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.